This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardlytics, Inc. (CDLX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cardlytics, Inc. (CDLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cardlytics, Inc. (CDLX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics, Inc. (CDLX) delivered earnings and revenue surprises of 47.83% and 11.23%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cardlytics, Inc. (CDLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardlytics, Inc. (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fiserv (FISV) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Fiserv's (FISV) second-quarter 2019 results to reflect revenue growth and better operating performance.
IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA's (IQV) second-quarter 2019 results are likely to benefit from continued market penetration of analytics and technology-enabled offerings across the company's TAS and R&DS businesses.
Here's Why Momentum Investors Will Love Cardlytics, Inc. (CDLX)
by Zacks Equity Research
Does Cardlytics, Inc. (CDLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardlytics, Inc. (CDLX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Cardlytics, Inc. (CDLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
All You Need to Know About Cardlytics, Inc. (CDLX) Rating Upgrade to Strong Buy
by Zacks Equity Research
Cardlytics, Inc. (CDLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Moving Average Crossover Alert: Cardlytics
by Zacks Equity Research
Cardlytics, Inc. (CDLX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Cardlytics (CDLX) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Cardlytics (CDLX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Zacks.com featured highlights include: ADTRAN, Cardlytics, Molina and Carlisle
by Zacks Equity Research
Zacks.com featured highlights include: ADTRAN, Cardlytics, Molina and Carlisle
Bet on These 4 Top Liquid Stocks for Solid Returns
by Zacks Equity Research
Here are four impressive liquid stocks that are poised to offer marvelous returns.
New Strong Buy Stocks for May 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday:
Cardlytics, Inc. (CDLX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cardlytics, Inc. (CDLX).
Cardlytics, Inc. (CDLX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Cardlytics, Inc. (CDLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cardlytics, Inc. (CDLX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardlytics, Inc. (CDLX) delivered earnings and revenue surprises of 37.84% and -0.03%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cardlytics, Inc. (CDLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardlytics, Inc. (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Verisk (VRSK) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Organic growth, lower tax rate and contributions from acquisitions are likely to boost Verisk's (VRSK) Q4 results.
Dun & Bradstreet (DNB) Misses Q2 Earnings, Unveils Sale Plan
by Zacks Equity Research
Dun & Bradstreet's (DNB) second-quarter 2018 results were negatively impacted by timing shifts of several large contracts.
Delphi Technologies (DLPH) Beats on Q2 Earnings, Tweaks View
by Zacks Equity Research
Delphi Technologies (DLPH) second-quarter 2018 earnings decline year over year but sales improve.
Genpact (G) Q2 Earnings Beat Estimates, '18 Revenue View Up
by Zacks Equity Research
Genpact (G) second-quarter 2018 earnings fall year over year due to higher tax rate.
Navigant (NCI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Navigant (NCI) rides on continued strong demand across most of its businesses and disciplined cost management.
CRA International (CRAI) Q2 Earnings Beat, Revenue View Up
by Zacks Equity Research
CRA International (CRAI) second-quarter 2018 results benefit from strength across services and geographies.
Avis Budget (CAR) Earnings to Reflect Volume Growth in Q2
by Zacks Equity Research
The spring and summer vacations represent the peak season for Avis Budget (CAR).
4 Business Services Stocks Poised to Beat Earnings Estimates
by Zacks Equity Research
The business services sector continues to benefit from a strong U.S. economy, reduced tax rates, robust manufacturing and non-manufacturing activities.